Introduction
The prevalence of renal dysfunction is high among patients hospitalized for acute heart failure syndromes (AHFS) and is an important predictor of clinical outcomes. 1 Furthermore, worsening renal function (WRF) may occur during hospitalization and is an adverse prognostic indicator. 2 However, very few registries and clinical trials have prospectively monitored parameters of renal function during hospitalization and post-discharge. 3 As a result, patients hospitalized for worsening chronic heart failure (HF) and reduced left ventricular ejection fraction (LVEF) who develop WRF, particularly after discharge, have not been wellcharacterized. The available data addressing renal function in AHFS is primarily based on retrospective analyses, 4 -6 casecontrol or cohort studies, 7 -9 post hoc reviews of clinical trial databases, 10, 11 and meta-analyses. 2 To the best of our knowledge, with one exception, 3 published studies have only assessed in-hospital WRF. 4 -7 The Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) global trial represents a unique opportunity to perform an in-depth clinical characterization of the patients hospitalized for HF with respect to the development of WRF either during hospitalization or soon after discharge and its impact on clinical outcomes.
Methods

Study design
The study design of the EVEREST trial has been previously reported. 12 EVEREST was a prospective, international, randomized, double-blind, placebo-controlled trial designed to explore both the short-and longterm impact of tolvaptan, a vasopressin-2 receptor antagonist, in patients .18 years of age hospitalized for worsening HF with an LVEF ,40% and presenting with two or more signs of fluid overload [dyspnoea, oedema, or jugular venous distention (JVD)]. 13, 14 Institutional review board or Ethics Committee approval was obtained at each site and all participants provided written informed consent. Participants were randomized within 48 h of hospitalization to receive either oral tolvaptan (30 mg/day) or matching placebo, both in addition to standard therapy. Background HF therapy was left to the discretion of the treating physician, but guideline-based recommendations for optimal medical therapy were included in the study protocol. Significant exclusion criteria included refractory end-stage HF, haemofiltration or dialysis, supine systolic blood pressure (SBP) ,90 mmHg, and serum creatinine (sCr) concentration .3.5 mg/dL.
Since tolvaptan acts on vasopressin receptors in the kidneys, the current analysis was performed only on the placebo arm of the EVEREST study in order to focus on renal dysfunction in patients hospitalized for worsening HF and reduced LVEF receiving standard therapy.
Basic chemistries, body weight (BW), vital signs, physical examination, and symptom scores were collected at randomization, hospital Day 7 or discharge (whichever occurred first), and during follow-up clinic visits scheduled at weeks 1, 4, 8, and every 8 weeks thereafter. The first outpatient visit occurred 7 days after discharge for those subjects discharged on or before Day 10 or on Day 17 for patients still in the hospital on Day 10. For administrative reasons, some centres measured B-type natriuretic peptide (BNP) and others measured Nterminal proBNP (NT-proBNP), and we report data on both natriuretic peptides. Since the distributions of BNP and NT-proBNP measurements were highly skewed, values are reported as a median and inter-quartile range, or as log 10 transformed units.
For all analyses, two distinct time periods were defined: the in-hospital period (the time from randomization to discharge or Day 7, whichever occurred first) and the post-discharge period (the time from discharge or Day 7 to 4 weeks post-discharge).
Definitions
The long-term outcome study had two primary endpoints: all-cause mortality and a composite measure of cardiovascular (CV) death or hospitalization for HF. Each of the two primary outcome measures was analysed as time to first event. The primary endpoints for the present analysis were the same as those in the long-term EVEREST study.
Baseline renal function was expressed as the estimated glomerular filtration rate (eGFR) calculated using the abbreviated modification of diet in renal disease equation. 15 ). Worsening renal function was defined, according to previously published standards, as an absolute increase in sCr ≥0.3 mg/ dL. 3, 5, 8, 9, 11, 17, 18 Worsening blood urea nitrogen (BUN) was defined as a ≥25% increase 10 and worsening eGFR was defined as a ≥25% decrease in eGFR. 10, 11 For all measurements of worsening, the changes for each parameter measured were from randomization to discharge or Day 7 for the in-hospital period, and from discharge or Day 7 to 4 weeks post-discharge for the post-discharge periods.
Statistical analysis
Differences in baseline demographics, physical and laboratory findings, medical history, and medical, revascularization, and device therapies between eGFR groups were assessed using the Kruskal -Wallis test for continuous variables and the Pearson x 2 test for categorical variables.
Since treatment of acute HF results in changes in congestion and blood pressure, analysis of these changes with respect to WRF was performed. Since increases in BW have been shown to reliably reflect congestion in patients with HF, 19 the mean change in BW was compared between patients with and without WRF using the Kruskal -Wallis test. Similar analyses were performed for systolic blood pressure (SBP), diastolic blood pressure (DBP), a previously developed congestion score, 20 and natriuretic peptides. The composite measure of congestion was calculated on the Day of randomization, on Day 7 or discharge, and at the 4-week post-discharge clinic visit and included the following three individual components: orthopnoea (none, seldom, frequent, continuous), JVD (,6, 6 -9, 10 -15, .15 cm H 2 O), and oedema (absent/trace, slight, moderate, marked). Each measure of congestion was rated on a numeric scale of 0 -3 and summed for a composite congestion score ranging from 0 to 9. Outcomes were determined for subgroups defined by baseline renal function and by changes in renal function during the in-hospital and the post-discharge periods. Time-to-event outcomes were summarized using Kaplan-Meier survival curves for all-cause mortality and the combined CV mortality/HF hospitalization endpoint. Differences in outcomes between groups were summarized by a hazard ratio (HR) and 95% confidence intervals (CI) calculated using a Cox proportional hazards model. The model for adjustment was determined through a process of backward selection. The least significant baseline variables were removed until all remaining variables had a significance level of P , 0.05. For the in-hospital change analysis the baseline parameter of interest was added to the model. For the post-discharge change analysis, the baseline and discharge or Day 7 parameters of interest were added to model.
The sponsor performed database management according to a prespecified plan and the University of Wisconsin Statistical Data Analysis Center conducted all analyses using SAS software, version 8.2 (SAS Institute Inc, Cary, NC, USA) and R software (R Development Core Team, R Foundation for Statistical Computing, Vienna, Austria). All authors had full access to the data, take responsibility for its integrity, and have read and agree to the manuscript as written.
Results
Baseline characteristics
Of the 4133 patients enrolled in EVEREST and followed for a median of 9.9 months, 2061 were assigned to the placebo group and 2021 (98% of the placebo group) had baseline eGFR results. The distribution of baseline renal function for the study population was 8.5% high-normal (group 1), 39.3% low-normal (group 2), 44.4% moderately reduced (group 3), and 7.8% severely reduced (group 4) eGFR ( Table 1) . Patients with more severe renal dysfunction at baseline tended to be older, had lower blood pressure, presented with more clinical signs of HF, and were more likely to have a history of prior HF hospitalization. They also had higher BNP levels, more cardiac and non-cardiac co-morbidities, more atherosclerotic involvement (evidenced through history of coronary artery disease, peripheral arterial disease, and prior coronary revascularization) and a higher rate of prior device-related procedures. Measurements of congestion such as New York Heart Association class, JVD, rales, and pulmonary oedema were similar among groups. Patients with more severe renal dysfunction at baseline were less likely to be taking an angiotensin-converting enzyme inhibitors (ACE-Is), angiotensin receptor blockers (ARBs), or spironolactone at baseline or at discharge ( Table 2) .
In-hospital changes in renal function
During the in-hospital period, WRF was observed in 13.8% of patients. Worsening BUN occurred in 31.4% and worsening eGFR in 10.5% of patients. During this period, 35.2% had worsening of any of the three renal parameters, while 8.1% had worsening of all three parameters ( Figure 1 ).
Post-discharge changes in renal function
During the post-discharge period, 11.9% of the patients had WRF. Worsening BUN occurred in 22.2% and worsening eGFR in 8.6% of the patients. During this period, 27.4% had worsening of any parameter and 5.2% had worsening of all three parameters ( Figure 1) .
A detailed summary of renal parameters according to the presence or absence of WRF during the in-hospital and post-discharge periods is reported in Table 3 .
Changes in clinical variables and renal function
Changes in blood pressure, BW, congestion score, and natriuretic peptides according to the presence or absence of WRF during the in-hospital and post-discharge periods are reported in Table 4 . During the in-hospital period, SBP, DBP, BW, and log 10 BNP decreased in patients with and without WRF, although to a slightly greater extent in patients with WRF. Log 10 NT-proBNP, and congestion score decreased in patients with and without WRF.
During the post-discharge period, SBP, DBP, BW, and log 10 BNP decreased in patients with WRF, whereas they increased in patients without WRF. Congestion score and log 10 NT-proBNP increased slightly and to a similar degree in patients with and without WRF.
Renal function and outcomes
There was no association between baseline eGFR and all-cause mortality after multivariate analysis ( Table 5 and Figure 2 
Discussion
This retrospective analysis demonstrates that impaired baseline renal function is common in patients hospitalized for worsening HF with reduced LVEF receiving standard therapy, and a subset of patients may subsequently develop WRF both during hospitalization and in the early post-discharge period. Both baseline renal impairment and WRF predict poor outcomes. In-hospital and postdischarge WRF are associated with improvements in markers of congestion (e.g. BW and natriuretic peptides) and greater reductions in blood pressure.
In-hospital worsening renal function
The incidence of WRF reported in this study (13.8%) is comparable with estimates previously reported in the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) 10 and in the Organized
Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). 21 Although in the current analysis, the majority of patients experienced a reduction in blood pressure and major reductions in signs and symptoms of congestion during hospitalization, the patients who developed function parameters due to arterial underfilling, or due to kidney injury. 23, 24 The slightly greater reduction in BW and BP in patients with in-hospital WRF in the current study suggests that in most patients, WRF may more commonly occur as a result of the former mechanism, which may explain why WRF was found to be weakly predictive of long-term outcomes in this study. Although sCr, BUN, and eGFR have been traditionally used as markers of renal function and surrogates for renal damage, newer biomarkers may better predict kidney injury and therefore outcomes.
-27
Prevention of in-hospital WRF as an endpoint for efficacy and/or safety has received significant attention from both clinical trialists and regulatory authorities. 28 -30 However, our results suggest that enthusiasm for renal function as an efficacy endpoint for clinical trials and regulatory approval should be reevaluated for two reasons: 1) The incidence of WRF, as seen in this analysis and the recently completed PROTECT trial, is 15% or less 18 and 2) WRF during hospitalization is most likely related to arterial underfilling occurring as a result of aggressive decongestion therapy rather than worsening HF or kidney injury. Values are reported as mean (SD). WRF, worsening renal function; sCr, serum creatinine; BUN, blood urea nitrogen; eGFR, estimated glomerular filtration rate. Start and final measurements are measured at randomization and on discharge or Day 7, respectively, for the in-hospital period, and at discharge or Day 7 and 4 weeks post-discharge, respectively, for the post-discharge period.
Post-discharge worsening renal function
In our study, post-discharge WRF had a stronger relationship with worse outcomes than in-hospital WRF. Damman et al. 3 analysed sCr change between discharge and 6 months in the Coordinating Study Evaluating Outcome of Advising and Counseling in Heart Failure (COACH) trial and found it to be independently related to poor prognosis. However, since the incidence of cardiac events is higher in patients hospitalized for HF in the early post-discharge period, 31 an earlier assessment is more likely to detect changes that are predictive of post-discharge outcomes. Similar to patients who developed in-hospital WRF, patients who developed post-discharge WRF had a decrease in BW, BNP, and blood pressure. However, unlike the in-hospital trend, patients who did not develop WRF had slight increases in BW, BNP, and blood pressure post-discharge. The early post-discharge period is sometimes referred to as the 'vulnerable phase', where morbidity and mortality is the highest, and therefore a critical time-period to re-evaluate patients. 31, 32 Recent analyses of the OPTIMIZE-HF registry indicate that an early post-discharge visit is associated with a lower readmission rate in patients admitted for HF. 33 Our findings support the performance of such a visit for the evaluation and treatment of renal function, as targeting only those patients with WRF during hospitalization may miss an important subset of patients with WRF post-discharge.
31,32
Limitations A number of limitations are present in our study. First, this investigation was a post hoc analysis. However, parameters of renal function were prospectively collected at prespecified time points during hospitalization and post-discharge. In addition, long-term outcomes including all-cause mortality, CV mortality, and HF rehospitalization were independently verified by a separate adjudication committee, increasing the validity of these endpoints. Second, these data were collected in the context of a clinical trial with specific inclusion and exclusion criteria, potentially limiting the generalizability. For instance, excluding patients with a sCr .3.5 mg/dL did not account for patients with the most severe baseline renal dysfunction. Third, when analysing eGFR cutoffs, estimation of eGFR .60 mL/min/1.73 m 2 is known to be highly inaccurate, which may influence the analysis for up to 47% of the study population. 34 Fourth, when estimating the Cox proportional hazards model, there was evidence of non-proportional hazards with post-discharge worsening of sCr and eGFR for the CV death/HF hospitalization outcome. Nonetheless, the reported HRs remain simple, meaningful summaries of the average differences between groups over the follow-up period. Finally, the definitions of WRF utilized in this study, although commonly accepted, are arbitrary and GFR was not measured directly. Despite these limitations, the EVEREST trial is the largest study of AHFS to date, enrolling patients from 359 sites in North America, South America, and Europe. Baseline and follow-up data were carefully collected and validated.
Conclusions
The prevalence of renal dysfunction is high in patients hospitalized for HF with reduced LVEF. Worsening renal function may occur not only during hospitalization, but also in the early post-discharge period. Though both in-hospital and post-discharge WRF portend poor outcomes, this worsening may be partially explained by efforts to reduce congestion. It is desirable, however, to develop therapies that can reduce congestion without worsening renal function. Since worsening renal function during hospitalization is associated with a significant decrease in signs and symptoms of congestion, body weight and natriuretic peptides, which are good prognostic indicators, worsening renal function during hospitalization as an endpoint in clinical trials should be re-evaluated.
